コンテンツへスキップ
Merck
  • Uncoupling angiogenesis and inflammation in peripheral artery disease with therapeutic peptide-loaded microgels.

Uncoupling angiogenesis and inflammation in peripheral artery disease with therapeutic peptide-loaded microgels.

Biomaterials (2014-08-27)
Angela L Zachman, Xintong Wang, Jason M Tucker-Schwartz, Sean T Fitzpatrick, Sue H Lee, Scott A Guelcher, Melissa C Skala, Hak-Joon Sung
要旨

Peripheral artery disease (PAD) is characterized by vessel occlusion and ischemia in the limbs. Treatment for PAD with surgical interventions has been showing limited success. Moreover, recent clinical trials with treatment of angiogenic growth factors proved ineffective as increased angiogenesis triggered severe inflammation in a proportionally coupled fashion. Hence, the overarching goal of this research was to address this issue by developing a biomaterial system that enables controlled, dual delivery of pro-angiogenic C16 and anti-inflammatory Ac-SDKP peptides in a minimally-invasive way. To achieve the goal, a peptide-loaded injectable microgel system was developed and tested in a mouse model of PAD. When delivered through multiple, low volume injections, the combination of C16 and Ac-SDKP peptides promoted angiogenesis, muscle regeneration, and perfusion recovery, while minimizing detrimental inflammation. Additionally, this peptide combination regulated inflammatory TNF-α pathways independently of MMP-9 mediated pathways of angiogenesis in vitro, suggesting a potential mechanism by which angiogenic and inflammatory responses can be uncoupled in the context of PAD. This study demonstrates a translatable potential of the dual peptide-loaded injectable microgel system for PAD treatment.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
テトラヒドロフラン, inhibitor-free, suitable for HPLC, ≥99.9%
Sigma-Aldrich
ジクロロメタン, suitable for HPLC, ≥99.8%, contains amylene as stabilizer
Sigma-Aldrich
ジエチルエーテル, anhydrous, ACS reagent, ≥99.0%, contains BHT as inhibitor
Sigma-Aldrich
ジクロロメタン, contains 40-150 ppm amylene as stabilizer, ACS reagent, ≥99.5%
Sigma-Aldrich
トルエン, ACS reagent, ≥99.5%
Sigma-Aldrich
ジクロロメタン, HPLC Plus, for HPLC, GC, and residue analysis, ≥99.9%, contains 50-150 ppm amylene as stabilizer
Sigma-Aldrich
テトラヒドロフラン, contains 200-400 ppm BHT as inhibitor, ACS reagent, ≥99.0%
Sigma-Aldrich
トルエン, suitable for HPLC, 99.9%
Sigma-Aldrich
ジエチルエーテル, suitable for HPLC, ≥99.9%, inhibitor-free
Sigma-Aldrich
テトラヒドロフラン, anhydrous, ≥99.9%, inhibitor-free
Sigma-Aldrich
トルエン, HPLC Plus, for HPLC, GC, and residue analysis, ≥99.9%
Sigma-Aldrich
ジクロロメタン, anhydrous, ≥99.8%, contains 40-150 ppm amylene as stabilizer
Sigma-Aldrich
テトラヒドロフラン, anhydrous, contains 250 ppm BHT as inhibitor, ≥99.9%
Sigma-Aldrich
ジエチルエーテル, ACS reagent, anhydrous, ≥99.0%, contains BHT as inhibitor
Sigma-Aldrich
トルエン, anhydrous, 99.8%
Sigma-Aldrich
トルエン, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99.7% (GC)
Sigma-Aldrich
ジクロロメタン, puriss. p.a., ACS reagent, reag. ISO, ≥99.9% (GC)
Sigma-Aldrich
ジエチルエーテル, contains BHT as inhibitor, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99.8% (GC)
Sigma-Aldrich
ジクロロメタン, ACS reagent, ≥99.5%, contains 40-150 ppm amylene as stabilizer
Sigma-Aldrich
ジエチルエーテル, contains 1 ppm BHT as inhibitor, anhydrous, ≥99.7%
Sigma-Aldrich
テトラヒドロフラン, ≥99.0%, contains 200-400 ppm BHT as inhibitor, ReagentPlus®
Sigma-Aldrich
テトラヒドロフラン, contains 250 ppm BHT as inhibitor, puriss. p.a., ACS reagent, reag. Ph. Eur., ≥99.9%
Sigma-Aldrich
トルエン, ACS reagent, ≥99.5%
Sigma-Aldrich
ジクロロメタン, puriss., meets analytical specification of Ph. Eur., NF, ≥99% (GC)
Supelco
ジクロロメタン, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
テトラヒドロフラン, ACS reagent, ≥99.0%, contains 200-400 ppm BHT as inhibitor
Sigma-Aldrich
ジエチルエーテル, reagent grade, ≥98%, contains ≤2% ethanol and ≤10ppm BHT as inhibitor
Sigma-Aldrich
ジエチルエーテル, ACS reagent, ≥98.0%, contains ≤2% ethanol and ≤10ppm BHT as inhibitor
Sigma-Aldrich
トルエン, Laboratory Reagent, ≥99.3%
Supelco
トルエン, analytical standard